Global Leading Market Research Publisher QYResearch announces the release of its latest report *"Hepatitis C Treatment Direct-Acting Antiviral (DAA) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Hepatitis C Treatment Direct-Acting Antiviral (DAA) market, including market size, share, demand, industry development status, and forecasts for the next few years. For hepatologists, infectious disease specialists, and public health policymakers, the treatment landscape for hepatitis C virus (HCV) has been revolutionized by direct-acting antivirals (DAAs) – oral medications that target specific non-structural proteins of the virus (NS3/4A protease, NS5A, NS5B polymerase) to achieve sustained virologic response (SVR) rates exceeding 95%, effectively curing HCV infection. Prior to DAAs, interferon-based regimens had low efficacy (<50%), severe side effects (flu-like symptoms, depression, cytopenias), and long treatment duration (48 weeks). DAAs offer all-oral, short-course therapies (8-24 weeks), well-tolerated, with minimal drug-drug interactions. The global market for Hepatitis C Treatment Direct-Acting Antiviral (DAA) was estimated to be worth USmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/5975074/hepatitis-c-treatment-direct-acting-antiviral--daa Understanding Direct-Acting Antivirals: HCV Cure Mechanisms Direct-acting antivirals are small molecule inhibitors that target specific HCV replication steps. Unlike host-targeted agents (immunomodulators), DAAs directly bind viral enzymes. Three major classes: NS3/4A protease inhibitors: Glecaprevir, grazoprevir, paritaprevir, voxilaprevir. Block viral polyprotein cleavage, preventing replication complex formation. NS5A inhibitors: Ledipasvir, velpatasvir, daclatasvir, elbasvir, ombitasvir. Disrupt viral RNA replication and virion assembly. NS5B polymerase inhibitors – nucleoside/nucleotide: Sofosbuvir (prodrug, active metabolite). Chain terminator, incorporated into viral RNA. NS5B non-nucleoside inhibitors: Dasabuvir (less common). Allosteric inhibitor. Modern DAA regimens combine 2-3 classes (e.g., sofosbuvir/velpatasvir – NS5B+NS5A), offering pangenotypic coverage (effective across all HCV genotypes 1-6) or genotype-specific (restricted to certain genotypes). Market Segmentation by Type Pangenotypic DAAs (Dominant and Fastest-Growing Segment): Effective against all six major HCV genotypes (1-6) irrespective of subtype. Advantages: No genotyping required before treatment, simplifies prescribing (primary care settings, low-resource regions). Key products: Sofosbuvir/velpatasvir (Epclusa® – Gilead): Approved 2016, 12 weeks, pangenotypic. Also sofosbuvir/velpatasvir/voxilaprevir (Vosevi® – for retreatment). Glecaprevir/pibrentasvir (Mavyret® / Maviret® – AbbVie): Approved 2017, 8 weeks for non-cirrhotic patients, pangenotypic. Shortest regimen. Sofosbuvir + daclatasvir (off-label? limited genotypic coverage? daclatasvir pangenotypic? daclatasvir genotype 1-4, not 5-6 but used off-label). Pangenotypic share >70% of market in developed countries (US, EU, Japan), increasing in low/middle-income countries (simplify logistics). WHO recommends pangenotypic DAAs (Epclusa, Mavyret) for HCV elimination programs. Genotype-Specific or Polygenotypic DAAs (Declining Segment): Effective against subset of genotypes (e.g., genotype 1, 3, or 1-3). Require genotyping before treatment – adds cost, complexity, delays. Examples: Ledipasvir/sofosbuvir (Harvoni® – Gilead): Genotype 1, 4, 5, 6 (not 2, 3). Elbasvir/grazoprevir (Zepatier® – Merck): Genotype 1, 4. Ombitasvir/paritaprevir/ritonavir (Technivie™ – AbbVie, discontinued?). Daclatasvir + sofosbuvir (Daklinza® – BMS, genotype 1-4). Sofosbuvir + ribavirin (non-DAA combination) – genotype 2. Genotype-specific share declining as pangenotypic become generic (lower cost) and preferred for simplicity. However, some national guidelines still use genotype-specific for cost reasons (if pangenotypic not reimbursed). Also, for retreatment after pangenotypic failure, genotype-specific may be used (resistance testing). Market Segmentation by Application (End-User) Hospital (Largest, ~60-65% of market value): HCV treatment historically managed by hepatologists, gastroenterologists, infectious disease specialists in hospital outpatient clinics or inpatient settings (complicated cases – cirrhosis, decompensated liver disease, liver transplant recipients, HIV co-infection, renal impairment). Hospital setting allows access to diagnostics (genotyping, fibrosis staging – transient elastography, biopsy), monitoring (liver function tests, adverse effects), and specialty pharmacy. DAA dispensing often via hospital pharmacy (expensive drugs, prior authorization requirements, specialty distribution). However, shift to community settings. Clinic (Fastest-Growing, ~25-30%): Community clinics (primary care, federally qualified health centers, addiction treatment centers, harm reduction programs, HIV clinics) increasingly treating HCV with DAA pangenotypic regimens. Task-shifting from specialists to mid-level providers (nurse practitioners, physician assistants) – expanded access. Patient navigation support. Telemedicine HCV treatment (particularly post-COVID) allows remote prescribing. Clinic segment growing as DAA prices drop (generics). Others (Prisons, substance use treatment centers, mobile health units): High prevalence populations (incarcerated persons, people who inject drugs). DAA treatment in these settings reduces transmission, improves outcomes. Public health initiatives. Competitive Landscape and Exclusive Market Observation (2025–2026) Key Players: Gilead Sciences (market leader, pioneered DAA with sofosbuvir (2013), Harvoni (2014), Epclusa (2016), Vosevi (2017). Extensive patent portfolio, licensing agreements (voluntary licenses with generic manufacturers for low/middle-income countries). Estimated >50% market share historically, now declining as generics enter.), Bristol Myers Squibb (daclatasvir – used in combination with sofosbuvir, BMS exited HCV? uncertain, generic now.), AbbVie (Mavyret, glecaprevir/pibrentasvir – pangenotypic, short duration 8 weeks, strong market share particularly in Europe, North America, Japan. Patient assistance program), Johnson & Johnson (no current DAA? moved away), Boehringer Ingelheim (no DAA), Merck (Zepatier – elbasvir/grazoprevir, genotype 1,4, also no longer active), Kawin Technology (Chinese biotech, generic DAAs for domestic market). Segmentation note: The list includes historical players (BMS, J&J, Boehringer) who have exited or reduced HCV focus. Current market dominated by Gilead, AbbVie (pangenotypic) and generics. Exclusive Industry Insight (H1 2026): The DAA market is in a post-patent expiry, generic-driven, decreased revenue phase but increased access phase: Peak market (2015-2016): Global sales >US20billion(Sovaldi10B+, Harvoni 13B+).Prices:US84,000 for 12-week course. Cure rates high, but many patients untreated (cost). Current (2025-2026): Patent expiry in major markets (Epclusa US patent expires 2028? remains? generic ledipasvir/sofosbuvir available since 2020 in some regions). Pangenotypic generics available (India, Egypt, China, Brazil) at 500−2000for12−weekcourse.Marketvalueshrinking(annual 5-7B) but patient numbers increasing (WHO elimination targets). Gilead, AbbVie shifting to lower-margin generics partnerships and access licensing. WHO elimination goal: WHO targets HCV elimination (90% diagnosed, 80% treated) by 2030. Global funding (Global Fund, Unitaid, World Bank, national programs) expanding DAA access. Treatment volumes rising 10-15% annually in low/middle-income countries. Patent landscape: Gilead granted voluntary non-exclusive licenses to >100 generic manufacturers (via Medicines Patent Pool) for 117 countries (low/middle income). But middle-income countries (Brazil, China, India, South Africa, Russia) excluded some? Brazil compulsory license for sofosbuvir 2025? dynamic. AbbVie also licensing Mavyret generic. User case: Egypt (2025) – highest HCV prevalence globally (10%+ population). National screening program treated >4 million patients with generic DAAs (sofosbuvir/daclatasvir, later Epclusa generics). Achieved reduced new infections, modeled to eliminate HCV by 2030. Procurement volume 500,000+ courses annually. Packaging: high barrier blister packs (moisture protection, stability tropical climate). Example. User case 2: India (2025) – National Viral Hepatitis Control Program procures generic pan-genotypic DAAs (sofosbuvir/velpatasvir) at 150−200per12−weekcourse(domesticmanufacturers:Mylan,Hetero,Cipla,Natco).Treated>1millionpatientssinceprograminception.Costreductionfrom>80,000 (originator) to <$200 (generic) – paradigm shift. Technical Deep Dive: Pangenotypic Coverage – Mechanism HCV has 6 major genotypes (1-6) and >100 subtypes. Different genotypes have varying amino acid sequences in drug target regions (NS3, NS5A, NS5B) causing variable susceptibility. Pangenotypic DAAs are designed with: High genetic barrier to resistance: Require multiple mutations before clinical resistance (e.g., sofosbuvir targets NS5B conserved polymerase active site, mutations impair viral fitness). Broad activity across variants: Velpatasvir (NS5A inhibitor) activity across all 6 genotypes (IC50 <10 nM). Glecaprevir (protease inhibitor) retains activity despite common resistance mutations. Combination classes: Sofosbuvir+velpatasvir (two different mechanisms) reduces risk of resistance emergence, synergistic effect. Pangenotypic eliminates need for genotyping – simplifies treatment, reduces costs, improves access. Future Outlook (2026–2032): Drivers, Generic Erosion, and Elimination Growth Drivers: WHO elimination targets (2030): 80% treatment coverage required. Current global treatment rate ~15-20% of infected (varies). Significant volume growth needed. International funding expanding. Pangenotypic generics increasing: Price declines (500→100 over 5 years). More countries include in essential medicines list. Simplified care models: Nurse-administered, pharmacist-led, primary care based, rapid testing (point-of-care HCV RNA). Less specialist dependence. More patients treated. Screening expansion: Universal one-time screening (US CDC recommends all adults >18). Increased diagnosis leading to treatment. Constraints: Reinfection: Treated people who inject drugs (PWID) can be reinfected (reuse needles). Requires re-treatment, monitoring. Reduces elimination. Lost to follow-up: Patients diagnosed but not linked to care (stigma, drug/alcohol abuse, homelessness). Status unknown. Low coverage in high-burden countries: Nigeria, Pakistan, India, China – millions infected, health system capacity insufficient. Requires global funding. Emerging technologies: Single-tablet pan-genotypic short-course (4 weeks) for non-cirrhotic patients (investigational). Long-acting injectable DAAs (3-6 months depot) for adherence challenges (prisoners, PWID). Clinical trials Phase II. The market projected continued revenue decline (CAGR -5% to -10% due to generic erosion) but treatment volumes increase (CAGR +5-10%). Pangenotypic >90% share. Hospital share declines (shift to clinics, community). Developed country market (US, EU) high but compacting. Low/middle-income growth. Contact Us If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp